Selective HDAC1 and HDAC2 inhibitors
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.
1. A method of treating cancer mediated by HDAC1 or HDAC2 in a subject in need thereof, comprising administering to the subject a compound selected from
and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein the cancer is lung cancer.
4. The method of claim 3 , wherein the lung cancer is non-small cell lung cancer (NSCLC).
5. The method of claim 1 , wherein the cancer is breast cancer.
6. The method of claim 1 , wherein the cancer is a leukemia.
7. The method of claim 1 , wherein the cancer is a lymphoma.
8. The method of claim 7 , wherein the lymphoma is Hodgkin's lymphoma.
9. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.